Sudeep Pharma
November 21, 2025 – November 25, 2025
| Price | ₹563 - ₹593 |
| GMP Rumors * | ₹0 |
|---|---|
| Lot size | 25 |
| Issue size | ₹895.00 cr |
| Allotment | Nov 26, 2025 |
| Listing | Nov 28, 2025 |
Sudeep Pharma Lot(s) Distribution
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 25 | 14825 | 211298 |
| sHNI | 14 | 350 | 207550 | 2156 |
| bHNI | 68 | 1700 | 1008100 | 4312 |
Sudeep Pharma Reservation
| Category | Shares Offered | % |
|---|---|---|
| QIB | 7546375 | 50% |
| HNI | 2263912 | 15% |
| Retail | 5282462 | 35% |
| Total | 15092749 | 100% |
Sudeep Pharma About
IPO Details
| Total Issue Size | 1,50,92,749 shares (aggregating up to ₹895.00 Cr) |
| Fresh Issue | 1,602,023 shares (aggregating up to ₹95.00 Cr) |
| Offer For Sale | 1,34,90,726 shares (aggregating up to ₹800.00 Cr) |
| Face Value | ₹1/- Per Share |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 11,13,46,602 shares |
| Share Holding Post Issue | * shares |
Key Performance Indicator (KPI)
| KPI | Jun-25 | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|---|
| ROE | 4.52% | 28.13% | 37.41% | 27.91% |
| ROCE | 5.50% | 29.82% | 41.17% | 29.40% |
| Debt/ Equity | 0.14 | 0.2 | 0.17 | 0.32 |
Company Financial (In ₹Crore)
| Period Ended | Jun-25 | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|---|
| Assets | 922.26 | 717.17 | 513.87 | 420.11 |
| Total Income | 130.08 | 511.33 | 465.38 | 438.26 |
| Profit After Tax | 31.27 | 138.69 | 133.15 | 62.32 |
| EBITDA | 48.57 | 199.28 | 187.76 | 98.64 |
| NET Worth | 688.32 | 497.53 | 359.07 | 226.29 |
| Reserves and Surplus | 668.52 | 481.11 | 354.59 | 221.88 |
| Total Borrowing | 135.97 | 135.25 | 75.03 | 82.26 |
COMPARISON WITH INDUSTRY PEERS
*Company does not have any peer group company for comparison with Industry Peer.
About Company
Sudeep Pharma Limited, incorporated in 1989, is engaged in the manufacturing of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients, catering to customers in over 100 countries.
The company operates six manufacturing facilities with a total production capacity of 50,000 MT, focusing on mineral products such as calcium, iron, magnesium, zinc, potassium, and sodium.
Sudeep Pharma offers a wide portfolio of 200+ products serving a diverse set of industries including pharmaceuticals, food, and nutrition.
The company has robust R&D capabilities, supported by in-house laboratories and pilot-scale facilities dedicated to the development of mineral salts and excipients.
Product Portfolio Includes:
- Pharmaceutical, Food & Nutrition Business
- Specialty Ingredients Business
- Triturates
Strength
Market Leadership with a Diversified Portfolio: The company is a leading manufacturer of pharmaceutical, food, nutrition, and specialty ingredients (as of June 30, 2025), with strong positioning in mineral-based products and iron phosphate, along with a wide range of specialty food ingredients like encapsulated preservatives.
Robust and Compliant Manufacturing Infrastructure: The company operates four manufacturing facilities with 12 production lines across Gujarat and Ireland, spanning 68,446 sq. meters and offering an annual capacity of 72,246 MT, ensuring strong compliance and efficient production capabilities.
Strong R&D Capabilities Driving Innovation: With two R&D facilities and a dedicated team of 41 professionals, the company focuses on particle engineering, improving shelf life, nutrient bioavailability, and formulation solutions, supported by advanced equipment to enhance technology, sustainability, and product expansion.
Weakness
High Revenue Dependence on Limited Customers: A significant portion of revenue comes from a small number of customers, and losing any of them or facing reduced demand could negatively impact business, financial performance, and cash flows.
Regulatory and Quality Compliance Risks: The company’s manufacturing facilities undergo regular inspections and must comply with strict standards set by global agencies like USFDA, EXCiPACT, FSSC, WHO-GMP, ISO, and HACCP. Any quality issues or non-compliance could result in regulatory action and reputational damage.
Operational Disruption Risks: Manufacturing and R&D operations are exposed to risks such as equipment failure, industrial accidents, regulatory non-compliance, natural disasters, and infectious disease outbreaks. Any slowdown or shutdown could adversely affect business, results, and cash flows.
Sudeep Pharma Lead Manager(s)
Sudeep Pharma Address
129/1/A,
GIDC Estate,
Nandesari,
Vadodara, Gujarat, 391340
Phone: +91 265 284 0656
Email: cs.sudeep@sudeepgroup.com
Website: https://www.sudeeppharma.com/
Sudeep Pharma Registrar
MUFG Intime India Private Limited (Link Intime)
Link Intime India Private Ltd
C 101, 247 Park,
L.B.S.Marg Vikhroli (West),
Mumbai - 400083
Sudeep Pharma Reviewers
| Reviewer | Recommendation | File |
|---|